FILTER

Refine your search with the following facets to narrow down your results.

9 Current news of Cipher Pharmaceuticals

Cipher Pharmaceuticals acquires INNOCUTIS Holdings

15-Apr-2015 - Onxeo S.A. announced Cipher Pharmaceuticals' acquisition of INNOCUTIS Holdings LLC, the licensee of Sitavig® in the USA. As a major step in the growth strategy of Cipher Pharmaceuticals, this acquisition provides Cipher with a commercial infrastructure and a talented sales team for the USA. "We ...

acquisitions dermatology

Cipher achieves major milestone with FDA approval for CIP-TRAMADOL ER

12-May-2010 - Cipher Pharmaceuticals Inc. announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults. "This represents our second FDA approval - a major achievement for ...

chronic pain food pain +2

Cipher appoints Dr. William Claypool to Board of Directors

05-Nov-2009 - Cipher Pharmaceuticals Inc. (announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors. Since October 2008, Dr. Claypool has been a Senior Partner at Pennmark Associates, LLC, a pharmaceutical development consulting firm. Prior to that, Dr. Claypool served as ...

consulting medicine

Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN

08-Aug-2008 - Cipher Pharmaceuticals Inc. announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, sell ...

acne clinical trials dermatology +2

Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN

09-Jun-2008 - Cipher Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-ISOTRETINOIN, the Company's novel formulation of the acne medication isotretinoin. The required issue and publication fees will now be paid so that the patent ...

acne food

Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN

09-Jun-2008 - Cipher Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-ISOTRETINOIN, the Company's novel formulation of the acne medication isotretinoin. The required issue and publication fees will now be paid so that the patent ...

acne food

Cipher appoints new Chief Executive Officer

10-Aug-2006 - Cipher Pharmaceuticals Inc. announced that, effective August 8, 2006, Larry Andrews, President of Cipher, has been appointed Chief Executive Officer of the Company. Dr. John Mull has retired from the position of Chief Executive Officer, but will remain Chairman of the Board of Directors. Mr. ...

Eli Lilly Hoffmann-La Roche

Cipher receives Health Canada approval of CIP-Fenofibrate

22-Feb-2006 - Cipher Pharmaceuticals Inc. announced that it has received final approval from Health Canada for CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Health Canada has issued a Notice of Compliance for ...

food

Cipher reaches agreement to dismiss patent litigation in United States for CIP-Fenofibrate

01-Jun-2005 - Cipher Pharmaceuticals Inc. announced that it has reached an agreement with Abbott Laboratories, Fournier Industrie et Santé and Laboratoires Fournier S.A. to dismiss all claims in the U.S. patent litigation related to CIP-Fenofibrate, Cipher's formulation of the active ingredient fenofibrate, ...

Abbott cholesterol food +1